来自MSN10 个月
Alcon’s dry eye drug achieves primary endpoints in Phase III trials
Switzerland-based Alcon’s dry eye disease drug ... and COMET-3 (NCT05360966) trials enrolled more than 930 patients, aged 30 years and older, with dry eye disease. The studies met their primary ...